Tirzepatide vs MOTS-c
Both Tirzepatide and MOTS-c are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Tirzepatide | MOTS-c |
|---|---|---|
| Evidence Grade | A+ | B |
| FDA Status | FDA-approved for weight management and type 2 diabetes | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | 2.5–15 mg weekly (subcutaneous injection) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 1,850 | 22 |
| Categories | weight-loss, metabolic | metabolic, longevity |
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.